Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
141. |
ECCT/22/03/06 | Sickle Cell Disease A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko 2. Fredrick Chite Asirwa 3. Bernhards Ogutu Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research institute (Kisumu county) 3. International Cancer Centre (Uasin Gishu county) 4. CREATES - Strathmore University Medical Centre (Nairobi City county) |
View |
142. |
ECCT/22/03/03 | HVTN 140/HPTN 101 A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101 |
Principal Investigator(s) 1. Josphat kosgei Site(s) in Kenya KEMRI WRP, KERICHO |
View |
143. |
ECCT/22/03/04 | VIBRI COVID-19-001/2021 A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda). |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute, |
View |
144. |
ECCT/22/03/07 | ELEVATUM A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA |
Principal Investigator(s) 1. Dr. Oscar Muwale Onyango 2. Dr. Muchai Gachago Site(s) in Kenya 1. The Nairobi Hospital (Nairobi City county) 2. City Eye Hospital (Nairobi City county) |
View |
145. |
ECCT/22/03/01 | The \"NOVATION-1\" Trial A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya 1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. KEMRI Kericho (Kericho county) 4. KEMRI Siaya (Kisumu county) 5. Kenyatta National Hospital (Nairobi City county) |
View |